Valuation : Clene Inc.

Market Cap 51.33M 44.2M 41.53M 37.96M 71.03M 4.85B 71.27M 491M 190M 2.49B 193M 189M 8.02B P/E 2026 *
-1.55x
P/E 2027 * -2.34x
Enterprise Value 46.73M 40.24M 37.8M 34.56M 64.66M 4.42B 64.88M 447M 173M 2.26B 175M 172M 7.3B EV / Sales 2026 *
187x
EV / Sales 2027 * 2.28x
Free-Float
83.03%
Yield 2026 *
-
Yield 2027 * -
1 day-3.63%
1 week-13.87%
Current month-10.05%
1 month-25.82%
3 months-33.16%
6 months-23.46%
Current year-34.41%
1 week 3.72
Extreme 3.72
4.42
1 month 3.72
Extreme 3.72
5.57
Current year 3.72
Extreme 3.72
8.67
1 year 3.72
Extreme 3.72
13.5
3 years 2.28
Extreme 2.2801
15.57
5 years 2.28
Extreme 2.2801
167
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 2013-03-31
Chief Tech/Sci/R&D Officer 67 2012-12-31
Director of Finance/CFO 57 2022-01-31
Director TitleAgeSince
Chairman 65 2015-10-31
Director/Board Member 53 2019-08-31
Director/Board Member 49 2020-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/13/26 Free

Founder

3,514 0.0275%
8/13/26 Free

Director

3,514 0.0275%
8/13/26 Free

Director

3,674 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
-3.63%-13.87%-31.13%-73.67% 51.33M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-1.52%+46.40%+86.87% 66.32B
-0.31%+4.04%-11.99%+457.82% 27.66B
+0.86%-6.86%+3.33%-14.78% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%-0.09%+24.64%-18.36% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.20%+6.79%+59.66%+159.50% 14.65B
Average -1.60%-1.66%+37.25%+161.54% 28.33B
Weighted average by Cap. -1.53%-0.46%+40.53%+146.28%

Financials

2026 *2027 *
Net sales 249K 215K 202K 184K 345K 23.56M 346K 2.39M 925K 12.07M 936K 916K 38.96M 23.27M 20.04M 18.82M 17.21M 32.19M 2.2B 32.3M 223M 86.27M 1.13B 87.35M 85.45M 3.63B
Net income -34.49M -29.7M -27.9M -25.51M -47.72M -3.26B -47.89M -330M -128M -1.67B -129M -127M -5.39B -31M -26.7M -25.08M -22.93M -42.89M -2.93B -43.04M -297M -115M -1.5B -116M -114M -4.84B
Net Debt -4.6M -3.96M -3.72M -3.4M -6.37M -435M -6.39M -44M -17.06M -223M -17.27M -16.9M -719M 1.8M 1.55M 1.46M 1.33M 2.49M 170M 2.5M 17.22M 6.67M 87.15M 6.76M 6.61M 281M
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
26-09-04 US$3.850 -3.63% 122,486
26-09-03 US$3.995 -3.97% 145,077
26-09-02 US$4.160 +1.34% 107,569
26-09-01 US$4.105 -4.09% 159,512
26-08-31 US$4.280 +1.18% 41,282
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.995USD
Average target price
32.20USD
Spread / Average Target
+706.01%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock